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ABSTRACT
Introduction: Information detailing the
experience of patients with light chain (AL)
amyloidosis is lacking. The primary aim of this
study was to gather data on the patient
experience to understand the challenges in
diagnosis and to gain insight into barriers to
accessing appropriate care.
Methods: Patients with amyloidosis, family
members, and caregivers were invited to
participate in an online 16-question survey
(available from January 29 to February 5,
2015). Participants with AL amyloidosis were
sent an eight-question follow-up survey.
Results: The initial survey was completed by
533 participants (follow-up survey completed
by 201 participants). AL amyloidosis was the
most common diagnosis. For 37.1% of
respondents, the diagnosis of amyloidosis was
not established until C1 year after the onset of
initial symptoms. Diagnosis was received after
visits to 1, 2, 3, 4, or C5 physicians by 7.6%,
23.5%, 20.3%, 16.8%, and 31.8% of
respondents, respectively. Correct diagnosis
was most often made by hematologists/
oncologists (34.1%). Treatments included
chemotherapy (63.1%) and stem cell
transplantation (38.9%) and were difficult to
tolerate for 54.1% of respondents. A significant
number of respondents felt uninformed about
clinical trials. Nevertheless, approximately half
(46.1%) believed that enrolling in a trial would
enhance their care.
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Conclusions: Establishing a diagnosis of
amyloidosis is difficult. Current treatments are
difficult to tolerate and do not substantially
improve quality of life for most patients. There
is an urgent need for well-tolerated therapies
with clear treatment benefit. Patient awareness
of clinical trials can be improved, especially
given that respondents indicated high
willingness to participate.
Keywords: Disease awareness; Early diagnosis;
Patient survey; Systemic amyloidosis;
Treatment
INTRODUCTION
Amyloidosis is a rare disorder characterized by
abnormal, misfolded proteins that accumulate
in various organs, causing progressive organ
damage [1, 2]. There are several types of
systemic amyloidoses; light chain (AL)
amyloidosis (Orpha number: ORPHA85443)
represents the most common type [3]. The
estimated incidence of AL amyloidosis is 8–12
persons per million per year [4–6]. In addition,
an estimated 10–15% of cases occur in
association with multiple myeloma. Based on
the incidence data, it is estimated that there are
30,000 to 45,000 patients living with AL
amyloidosis in the United States and the
European Union.
Clinical presentation of AL amyloidosis can
vary widely and depends on the extent and
number of organs affected. Initial symptoms at
onset are often nonspecific (e.g., weight loss,
fatigue). As the disease progresses, symptoms
reflect the organs involved, most commonly the
heart and the kidneys [5]. The goal of treatment
for patients with AL amyloidosis should be to
preserve and improve organ function with a
well-tolerated and effective disease-modifying
therapy. Despite recent advances in AL
amyloidosis diagnostic tools and treatment,
the early mortality rate remains high; the
1-year mortality rate is approximately 30%.
Unfortunately, by the time a diagnosis is made
and treatment is initiated, the disease has often
become advanced [4, 5].
In the absence of approved therapies for AL
amyloidosis, physicians use off-label multiple
myeloma therapies that target the abnormal
plasma cells responsible for the production of
the light chain precursor proteins without
consideration for the underlying organ
dysfunction in the patient [5, 7, 8]. Thus,
these treatments can be associated with
significant adverse events, and patients often
die before experiencing benefit from them [5]. A
substantial need remains for well-tolerated and
effective therapies that specifically target the
underlying cause of the disease: the misfolded
light chain proteins.
Despite the significant effects of AL
amyloidosis on patient quality of life, data
describing them are lacking. Detailing the
patient experience may identify ways to
improve patient care and disease outcomes.
The primary aim of this study was to gather
data on the patient experience to elucidate the
challenges in establishing a diagnosis of AL
amyloidosis and to gain insight into barriers to
accessing appropriate care.
METHODS
Patients with amyloidosis, their family
members, and their caregivers were invited
to participate in an anonymous online survey
through email and via the social media
channels of the Amyloidosis Foundation (www.
amyloidosis.org), the foundation’s Facebook page
(www.facebook.com/AmyloidosisFoundation), and
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an amyloidosis awareness group on
Facebook (www.facebook.com/groups/amyloidosis
awareness). The initial 16-question survey was
developed by the authors and was available
online to participants from January 29 to
February 5, 2015. After the initial survey was
completed, participants with AL amyloidosis
who provided contact information were sent
an eight-question follow-up survey by email.
The initial survey covered demographic
information, type of amyloidosis, symptoms,
organ involvement, diagnosis, amyloidosis
education, and clinical trial awareness. It was
expected that a high proportion of respondents
to the initial survey would be patients with AL
amyloidosis; therefore, the follow-up survey
focused on AL amyloidosis and consisted of
eight questions covering amyloidosis
treatments, treatment tolerance, and quality of
life before and after treatment.
Statistical Analysis
Data were evaluated using descriptive statistics
(Microsoft Excel 2013, Redmond, Washington).
Compliance with Ethics Guidelines
This article does not contain information on
any new studies in human or animal subjects
performed by any of the authors. All procedures
followed were in accordance with the ethical
standards of the responsible committee on
human experimentation (institutional and
national) and with the Helsinki Declaration of
1964, as revised in 2013. Informed consent was
obtained from all patients as a condition of
their inclusion in the study.
RESULTS
Participants
The initial survey was completed by 533
participants; 57.8% identified themselves as
patients, 33.8% identified themselves as family
members, and 8.3% identified themselves as
caregivers taking the survey on behalf of
patients (Table 1). The follow-up survey was
completed by 201 participants. Most
respondents were female (62.2%) and were
between 50 and 69 years of age (62.7%).
Diagnosis of Amyloidosis
Median age at diagnosis was 57 years (range
20–83 years). AL amyloidosis, reported by 71.7%
of respondents (Table 1), was the most common
diagnosis. The other types of amyloidosis were AA
amyloidosis (4.8%), hereditary transthyretin-
related amyloidosis (7.2%), hereditary
non–transthyretin-related amyloidosis (1.2%),
other (5.2%), and unknown (9.9%).
Most respondents (63.0%) reported that they
received a diagnosis of amyloidosis within
1 year of initial symptoms, whereas 37.1% of
respondents reported that diagnosis was
delayed for C1 year (Table 2). A substantial
proportion of respondents (31.8%) reported
visiting C5 different physicians before
receiving the diagnosis of amyloidosis, and
only 7.6% received the diagnosis after visiting
one physician (Table 2). The first doctor seen
was usually a primary care physician (64.9%).
Respondents were then often referred for a
second visit to a cardiologist (24.5%),
hematologist/oncologist (16.5%), nephrologist
(18.1%), or gastroenterologist (14.6%) (Fig. 1).
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Cardiologists, hematologists/oncologists, and
nephrologists had the most opportunities to
diagnose amyloidosis for respondents referred
to their specialties. Respondents also visited
other specialists, including internists,
neurologists, hepatologists, ophthalmologists,
and dermatologists.
Table 1 Characteristics of survey respondents
Respondents
Type of participant, n (%), n = 515
Patient 298 (57.8)
Family member 174 (33.8)
Caregiver 43 (8.3)
Sex, n (%), n = 519
Female 323 (62.2)
Male 196 (37.8)
Age group, n (%), n = 524
25–34 years 23 (4.4)
35–44 years 59 (11.3)
45–54 years 96 (18.3)
55–64 years 190 (36.3)
65–74 years 120 (22.9)
75 years or older 36 (6.9)
Median age at diagnosis, years (range) 57 (20–83)
Type of amyloidosis, n (%), n = 484
AL amyloidosis 347 (71.7)
AA amyloidosis 23 (4.8)










Gastrointestinal tract 27 (5.8)
Nervous system 26 (5.5)
Multiple 97 (20.7)
Please note that not all participants responded to all
questions. 533 participants completed the survey, but the
numbers in the table indicate those who answered each
particular survey question
AA inﬂammatory, AL light chain
Table 2 Establishment of amyloidosis diagnosis
Respondents
Time from initial symptoms to diagnosis of amyloidosis,
n (%), n = 459
\6 months 171 (37.3)
6–12 months 118 (25.7)
12–18 months 44 (9.6)
18–24 months 34 (7.4)
2–3 years 44 (9.6)
[3 years 48 (10.5)
Different physicians visited before establishment of a












Primary care physician 16 (4.0)
Othera 32 (8.0)
a Includes internists, hepatologists, ophthalmologists, and
dermatologists
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Respondents saw cardiologists more
frequently than hematologists/oncologists and
nephrologists, though cardiologists did not
typically diagnose the condition. Respondents
usually received the correct diagnosis from a
hematologist/oncologist (34.1%). Nephrologists
and cardiologists provided the correct diagnosis
for 22.6% and 18.7% of respondents,
respectively (Table 2).
Sixty-three percent of respondents had been
evaluated at an amyloidosis center (452 total
responses), although only 43.7% received
treatment at an amyloidosis center (444 total
responses).
Amyloidosis Symptoms and Organ
Involvement
The most common initial symptoms were
fatigue, shortness of breath, weakness,
neuropathy, and swelling of the legs and/or
tongue. Most respondents reported the heart
(36.7%) or the kidneys (28.1%) as the major
organ affected, with involvement of the
gastrointestinal tract (5.8%), nervous system
(5.5%) or liver (3.2%) reported less frequently
(Table 1). Multiple organ involvement was
reported by 20.7% of respondents.
AL Amyloidosis Diagnosis and Treatment
Among the participants with AL amyloidosis
who completed the follow-up survey, 39.2%
reported low quality of life before diagnosis,
31.2% reported average quality of life, and
29.7% reported great quality of life (199 total
responses). When asked how the diagnosis of
amyloidosis made the patient feel, 63.0%
reported feeling frightened, 31.0% depressed,
30.5% numb, 28.5% powerless, 25.5% hopeless,
18.5% relieved, and 18.0% angry (200 total
responses).
For patients with AL amyloidosis who
responded to the follow-up survey, treatment
consisted of chemotherapy in 63.1% of
respondents, stem cell transplantation in
38.9%, and solid organ transplantation in
7.6%. When asked how well treatment was
tolerated, 54.1% reported that it was somewhat
or very difficult, 20.4% reported neither easy
nor difficult, and 25.4% reported somewhat
easy (181 total responses). However, patients
Fig. 1 Types of physicians visited before diagnosis of amyloidosis
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receiving stem cell transplantation found
treatment to be much less tolerable than
patients receiving other types of treatment
(Table 3). Quality of life in patients receiving
any of these treatments was greatly improved
with treatment for 28.8% of respondents,
somewhat improved for 39.1%, and not
improved at all for 32.1% (184 total
responses). In particular, patients receiving
stem cell transplantation rated their quality of
life as having improved more substantially than
patients receiving other treatments (Table 3).
Amyloidosis Education
Of the 427 respondents who answered a question
pertaining to informationor educationalmaterial
received at the time of diagnosis about their
specific amyloidosis type, 39.3% received the
center’s own printed handouts, 34.4% received
another organization’s disease or treatment
literature, 29.3% received information on
support groups, 23.7% received clinical trial
information, and 40.0% reported receiving no
information or educational material.
Clinical Trial Awareness
In the initial survey, participants were asked to
score their answers regarding clinical trial
knowledge and access on a scale of 1 to 5,
from ‘‘Not at all’’ (score 1) to ‘‘Absolutely’’ (score
5) (Fig. 2). A significant number of respondents
felt uninformed about clinical trials; 71.6%
indicated a score of B3 regarding how
knowledgeable they were about clinical trials.
Most respondents also felt that they did not
have access to pertinent clinical trial
information; 68.8% indicated a score of B3
regarding access to clinical trial information.
Nevertheless, almost half (46.1%) said they
believed that a clinical trial would enhance
their medical care (score of C4), and 45.5%
reported that they would absolutely consider
enrolling in a clinical trial if they were well
informed. Forty-six percent of respondents also
reported that they did not know how to enroll
in a clinical trial. In the follow-up survey, 19.5%
of respondents reported that they had
participated in a clinical trial (190 total
responses).
Table 3 Tolerability and quality of life associated with stem cell transplantation compared with other treatments
Stem cell transplantation (n5 77) Other treatments (n5 124)
Tolerability, n (%) n = 75 n = 105
Very difﬁcult 20 (26.7) 13 (12.4)
Somewhat difﬁcult 28 (37.3) 37 (35.2)
Neither easy nor difﬁcult 14 (18.7) 22 (21.0)
Somewhat easy 13 (17.3) 33 (31.4)
Quality of life, n (%) n = 76 n = 108
Greatly improved 28 (36.8) 25 (23.1)
Somewhat improved 26 (34.2) 46 (42.6)
No improvement 22 (28.9) 37 (34.3)
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DISCUSSION
Despite the challenges facing health care
professionals in diagnosing AL amyloidosis,
the lack of available therapeutic options that
are effective and well tolerated, and the
subsequent impact on the patients involved,
no published information describes the patient
experience. This article represents the first such
description of the patient journey and the
challenges faced.
Establishing an early and accurate diagnosis
of amyloidosis is a challenge for patients. These
data demonstrate that most patients require
multiple physician visits to different medical
specialists, often spanning[1 year. Consistent
with the literature [5, 9, 10], most respondents
experience heart or kidney involvement.
Because of the high incidence of cardiac
symptoms (including shortness of breath)
associated with AL amyloidosis, primary care
physicians often refer their patients to
cardiologists. There is an opportunity and an
urgent need for all physicians, particularly
cardiologists, to diagnose amyloidosis earlier,
before the disease progresses to more advanced
stages. These data suggest that physicians in all
medical specialties have difficulty in
establishing a diagnosis of AL amyloidosis.
Interestingly, although AL amyloidosis is
typically considered to be a disease of the
elderly (older than 60 years of age), the
median age of respondents in our survey was
57 years, with 34.0% younger than 55 years of
age and 15.6% younger than 45 years of age.
Despite a selection bias inherent in a web-based
survey that may skew to younger persons,
younger patients are also probably
significantly underdiagnosed.
Considering that 54% of respondents had
difficulty in tolerating treatment and only 30%
of respondents reported a definite improvement
in quality of life, there is a need for therapies
clearly associated with treatment benefit. On
the other hand, benefits from therapy are more
likely to occur in early stages of the disease,
making early diagnosis essential for improving
outcomes for patients with systemic
amyloidosis [11]. Efforts to increase physician
awareness of the signs and symptoms and the
appropriate evaluation of AL amyloidosis have
the potential to improve patient outcomes.
Fig. 2 Clinical trial awareness and interest
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Survey responses indicate that patient
awareness of clinical trials and patient
education about the disease can be
considerably improved, especially because
respondents indicated a high willingness to
participate in clinical trials. Patient care can be
enhanced through education and information
to help patients feel empowered and
knowledgeable about their diagnosis and
treatment plan and through increased access
to support groups and relevant clinical trials.
We acknowledge the limitations in
controlling the quality of information
gathered through a web-based questionnaire.
Of note, there is a selection bias inherent to a
web-based survey that includes a younger
audience of patients and/or younger persons
involved in their care. However, we show that
this younger population, which likely
represents the most knowledgeable segment of
patients and which has the best access to
Internet resources, is not very well informed.
Additionally, there may be a bias with respect to
sex given that several studies have shown that
men have a higher incidence of most forms of
amyloidosis, whereas our respondents were
primarily women (62%). Web-based surveys
also do not control for the quality of care
patients are receiving; as such, it is not known
whether the respondents represent patients
with better or worse (or equivalent) care than
the average amyloidosis patient. Nevertheless,
this patient-centered initiative provides
important insights into the AL amyloidosis
patient experience from the time of diagnosis
through treatment of the disease.
CONCLUSIONS
This study highlights the value of and the need
for data on patient experience and quality of
life that can be reported in future studies as
part of patient-centered initiatives. Data from
this study and other studies can help to
identify areas in which diagnosis is delayed or
missed and can illustrate the need for early,
accurate diagnosis of amyloidosis to help
improve disease management and survival
outcomes.
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